JAMA Network Home
Sign In
Original Investigation

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents

JAMA Dermatology 10.1001/jamadermatol.2026.2853

August 12, 2026 at 11:00 AM EDT

Read the full article

In these 2 parallel phase 3 replicate randomized clinical trials, upadacitinib demonstrated a positive benefit-risk profile in adults and adolescents with severe AA. Upadacitinib may be a potentially effective treatment option for this patient population.

Corresponding Author: Arash Mostaghimi, MD, MPA, MPH, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02215 (amostaghimi@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2026.2853?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081226

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks